Table 3.
Best tumor response in HER2+ breast and gastric patients following treatment with MK-2206 and trastuzumab
| Patient | Age (years) | Sex | Diagnosis | MK-2206 dose | Prior lines of therapy | Trastuzumab-free interval (days) | Reason for discontinuing prior trastuzumab | Time to progressive disease/withdrawal (days) | Best response |
|---|---|---|---|---|---|---|---|---|---|
| A |
40 to 49 |
Female |
Breast cancer |
60 mg QOD |
5 |
41 |
Progressive disease |
167 |
SD (unconfirmed PR) |
| B |
50 to 59 |
Female |
Breast cancer |
60 mg QOD |
4 |
21 |
Progressive disease |
164 |
SD |
| C |
50 to 59 |
Male |
Gastric cancer |
200 mg QW |
2 |
0 |
Trastuzumab not given |
171 |
SD |
| D |
50 to 59 |
Female |
Breast cancer |
60 mg QOD |
8 |
48 |
Unknown |
219 |
SD |
| E |
40 to 49 |
Female |
Breast cancer |
135 mg QW |
5 |
68 |
Completed therapy |
105 |
SD |
| F |
50 to 59 |
Female |
Breast cancer |
60 mg QOD |
3 |
0 |
Progressive disease |
388 (withdraw)a |
PR |
| 7 | 50 to 59 | Female | Breast cancer | 135 mg QW | 5 | 28 | Progressive disease | 106 (withdraw) | CR |
CR, complete response; HER2, human epidermal growth factor receptor 2; PR, partial response; QOD, every other day; QW, every week; SD, stable disease. aPatient was on trial for 173 days and then continued receiving treatment after database lock for a total of 388 days before withdrawing due to skin rash.